CytomX Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

CytomX Therapeutics

27/03/2023 22:42

* CytomX Therapeutics Inc  CTMX.OQ  reported a quarterly
adjusted
loss of 43 cents​​ per share for the quarter ended in December.
The mean expectation of nine analysts for the quarter was for a
loss of 24 cents per share.
    * Revenue fell 95.2% to $946.00 thousand from a year ago;
analysts
expected $17.85 million. 
    * CytomX Therapeutics Inc's reported EPS for the quarter was
a
loss of 43 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * CytomX Therapeutics Inc shares had risen by 6.2% this
quarter.
    * The company reported a quarterly loss of $27.95 million.
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $2.73 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 27 at 09:42 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.24          -0.43          Missed
 Sep. 30 2022      -0.31          -0.35          Missed
 Jun. 30 2022      -0.36          -0.37          Missed
 Mar. 31 2022      -0.36          -0.37          Missed